Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-talazoparib
- Development stage
- Preclinical
- Lead developer
- University of Illinois, Urbana-Champaign
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-Talazoparib (also known as [18F]talazoparib or 18F-TZ) is an 18F-radiolabeled isotopologue of the potent poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib. It is developed as a positron emission tomography (PET) imaging radiotracer to non-invasively evaluate PARP1 and PARP2 expression levels, assess drug-target engagement, and aid in patient selection and therapy dose optimization for PARP inhibitor therapies. Synthesized via copper-mediated radiofluorination, 18F-talazoparib exhibits high affinity and specificity for PARP1/2, demonstrating blockable uptake in PARP-expressing tumor cells and favorable tumor-to-blood ratios in preclinical models of breast, prostate, ovarian, and pancreatic cancers.
- Other names
- (8S,9R)-[18F]talazoparib18F-TZ[18F]TZ[18F]talazoparibfluorine-18 talazoparibfluorine18 talazoparibfluorine 18 talazoparib
02
Targets
Pol II (RNA polymerase II elongation factors)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on 18F-talazoparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-talazoparib.